F Star Therapeutics, Inc. FSTX
We take great care to ensure that the data presented and summarized in this overview for F-star Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in FSTX
Top Purchases
Top Sells
About FSTX
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Insider Transactions at FSTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 08
2023
|
Eliot Forster PRESIDENT AND CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
73,959
-100.0%
|
$517,713
$7.12 P/Share
|
|
Mar 08
2023
|
Eliot Forster PRESIDENT AND CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
347,578
-82.45%
|
$2,433,046
$7.12 P/Share
|
|
Mar 08
2023
|
Louis Kayitalire CHIEF MEDICAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,019
-100.0%
|
$175,133
$7.12 P/Share
|
|
Mar 08
2023
|
Louis Kayitalire CHIEF MEDICAL OFFICER |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
29,236
-53.89%
|
$204,652
$7.12 P/Share
|
|
Mar 08
2023
|
Geoffrey Race Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,937
-100.0%
|
$27,559
$7.12 P/Share
|
|
Mar 08
2023
|
Neil Brewis CHIEF SCIENTIFIC OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,375
-100.0%
|
$65,625
$7.12 P/Share
|
|
Mar 08
2023
|
Neil Brewis CHIEF SCIENTIFIC OFFICER |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
105,088
-91.81%
|
$735,616
$7.12 P/Share
|
|
Mar 08
2023
|
Todd C Brady Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
15,004
-100.0%
|
$105,028
$7.12 P/Share
|
|
Mar 08
2023
|
Darlene M Deptula Hicks Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,539
-100.0%
|
$178,773
$7.12 P/Share
|
|
Mar 08
2023
|
Darlene M Deptula Hicks Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
30,898
-54.75%
|
$216,286
$7.12 P/Share
|
|
Mar 08
2023
|
David Arkowitz Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,386
-100.0%
|
$58,702
$7.12 P/Share
|
|
Mar 08
2023
|
Edward Benz Jr Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,385
-100.0%
|
$30,695
$7.12 P/Share
|
|
Mar 08
2023
|
Nessan Bermingham Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,328
-100.0%
|
$44,296
$7.12 P/Share
|
|
Mar 08
2023
|
Nessan Bermingham Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
97,547
-93.91%
|
$682,829
$7.12 P/Share
|
|
Jul 29
2022
|
Geoffrey Race Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,937
+50.0%
|
$0
$0.11 P/Share
|
|
Jul 29
2022
|
Eliot Forster PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
260,977
+38.24%
|
$0
$0.11 P/Share
|
|
Jul 29
2022
|
Neil Brewis CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
76,619
+40.1%
|
$0
$0.11 P/Share
|
|
Nov 02
2021
|
Louis Kayitalire CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
64
-0.06%
|
$384
$6.83 P/Share
|
|
Oct 04
2021
|
Louis Kayitalire CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
64
-0.12%
|
$448
$7.23 P/Share
|
|
Jul 02
2021
|
Louis Kayitalire CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,054
-1.9%
|
$8,432
$8.43 P/Share
|